Lecanemab, an investigational antibody also known as BAN2401, has been granted a fast track designation from the U.S. Food and Drug Administration (FDA), which may help speed up its development for the treatment of early Alzheimer’s disease. The antibody, developed jointly by Biogen and Eisai, is designed to bind to the protein amyloid-beta. This potentially allows the immune system to clear the protein before it forms the toxic clumps that drive the death of nerve…

You must be logged in to read/download the full post.